BOOK
Workbook for Rau's Respiratory Care Pharmacology - E-Book
Douglas S. Gardenhire | Robert J. Harwood
(2016)
Additional Information
Book Details
Abstract
The Workbook for Rau's Respiratory Care Pharmacology, 8th Edition is a valuable companion to the Rau text that offers a wide range of activities and practice exercises to further your understanding of challenging pharmacology material. Definitions, case studies, and content review break down complex concepts and help clarify key content from the text. NBRC exam-style questions, matching questions, fill-in-the-blank questions, and labeling exercises give you practice in applying those concepts and prepare you for the NBRC exam.
- Chapter objectives link workbook exercises to specific content from the textbook.
- A variety of pharmacology exercises hones your understanding of key terms and concepts.
- 80% more case-based scenarios help you develop the critical-thinking and analytical skills needed to succeed on the NBRC exam.
- 120 additional NBRC exam-style questions give you more practice with the types of questions you will encounter on the NBRC exam.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Workbook Rau's Respiratory Care\rPharmacology | ii | ||
| Copyright | iv | ||
| Contents | iii | ||
| Unit 1: Basic Concepts and Principles in Pharmacology | 1 | ||
| Chapter 1: Introduction to Respiratory Care Pharmacology | 1 | ||
| Objectives | 1 | ||
| Key Terms and Definitions | 1 | ||
| Pharmacology and the Study of Drugs | 2 | ||
| Sources of Drug Information | 2 | ||
| Sources of Drugs | 3 | ||
| Process of Drug Approval in the United States | 3 | ||
| The Prescription | 4 | ||
| Respiratory Care Pharmacology: An Overview | 4 | ||
| Related Drug Groups in Respiratory Care | 6 | ||
| National Board for Respiratory Care (NBRC) Testing Questions | 7 | ||
| Chapter 2: Principles of Drug Action | 11 | ||
| Chapter Objectives | 11 | ||
| Key Terms and Definitions | 11 | ||
| Drug Administration Phase | 12 | ||
| Pharmacokinetic Phase | 12 | ||
| Pharmacodynamic Phase | 16 | ||
| Pharmacogenetics | 18 | ||
| National Board for Respiratory Care (NBRC) Testing Questions | 18 | ||
| Chapter 3: Administration of Aerosolized Agents | 25 | ||
| Chapter Objectives | 25 | ||
| Key Terms and Definitions | 25 | ||
| Aerosol Therapy | 26 | ||
| Physical Principles of Inhaled Aerosol Drugs | 27 | ||
| Aerosol Devices for Drug Delivery | 28 | ||
| Clinical Application of Aerosol Delivery Devices | 34 | ||
| Age Guidelines for Use of Aerosol Devices | 35 | ||
| Endotracheal Tube Administration | 35 | ||
| National Board for Respiratory Care (NBRC) Testing Questions | 36 | ||
| Chapter 4: Calculating Drug Doses | 43 | ||
| Chapter Objectives | 43 | ||
| Key Terms and Definitions | 43 | ||
| Calculating Doses from Prepared-Strength Liquids, Tablets, and Capsules | 44 | ||
| Drug Amounts in Units | 47 | ||
| Calculating Doses from Percentage-Strength Solutions | 48 | ||
| National Board for Respiratory Care (NBRC) Testing Questions | 51 | ||
| Chapter 5: Central and Peripheral Nervous Systems | 57 | ||
| Chapter Objectives | 57 | ||
| Key Terms and Definitions | 57 | ||
| The Nervous System | 58 | ||
| Cholinergic and Anticholinergic Agents | 60 | ||
| Neural Control of Lung Function | 62 | ||
| National Board for Respiratory Care (NBRC) Testing Questions | 63 | ||
| Unit 2: Drugs Used to Treat the Respiratory System | 69 | ||
| Chapter 6: Adrenergic (Sympathomimetic) Bronchodilators | 69 | ||
| Chapter Objectives | 69 | ||
| Key Terms and Definitions | 69 | ||
| Clinical Indications for Adrenergic Bronchodilators | 71 | ||
| Mode of Action | 76 | ||
| Routes of Administration | 76 | ||
| Adverse Side Effects | 77 | ||
| beta-Agonist Controversy | 78 | ||
| Respiratory Care Assessment of beta-Agonist Therapy | 79 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 79 | ||
| Chapter 7: Anticholinergic (Parasympatholytic)Bronchodilators | 89 | ||
| Chapter Objectives | 89 | ||
| Key Terms and Definitions | 89 | ||
| Clinical Indications for USE | 90 | ||
| Specific Anticholinergic (Parasympatholytic) Agents | 90 | ||
| Pharmacologic Effects of Anticholinergic (Antimuscarinic) Agents | 91 | ||
| Mode of Action | 92 | ||
| Clinical Application | 93 | ||
| Combination Therapy: beta-Adrenergic Plus Anticholinergic Agents | 94 | ||
| Respiratory Care Assessment of Anticholinergic Bronchodilator Therapy | 95 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 95 | ||
| Chapter 8: Xanthines | 101 | ||
| Chapter Objectives | 101 | ||
| Clinical Indications for Use of Xanthines | 101 | ||
| Specific Xanthine Agents | 102 | ||
| General Pharmacologic Properties | 102 | ||
| Proposed Theories of Activity | 102 | ||
| Titrating Theophylline Doses | 103 | ||
| Dosage Schedules | 103 | ||
| Theophylline Toxicity and Side Effects | 104 | ||
| Factors Affecting Theophylline Activity | 104 | ||
| Clinical Application | 104 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 105 | ||
| Chapter 9: Mucus-Controlling Drug Therapy | 111 | ||
| Chapter Objectives | 111 | ||
| Key Terms and Definitions | 111 | ||
| Drug Control of Mucus: A Perspective | 112 | ||
| Physiology of the Mucociliary System | 113 | ||
| Nature of Mucus Secretion | 113 | ||
| Mucus in Disease States | 113 | ||
| Physical Properties of Mucus | 114 | ||
| Mucoactive Agents | 114 | ||
| Mucolytics | 114 | ||
| Expectorants | 116 | ||
| Mukokinetic Agents | 116 | ||
| Surface-Active Phospholipids | 116 | ||
| Mucoregulatory Medications | 116 | ||
| Antiproteases | 116 | ||
| Hyperosmolar Saline | 117 | ||
| Using Mucoactive Therapy with Physical Therapy and Airway Clearance Devices | 117 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 118 | ||
| Chapter 10: Surfactant Agents | 125 | ||
| Chapter Objectives | 125 | ||
| Key Terms and Definitions | 125 | ||
| Identification of Surfactant Preparations | 126 | ||
| Exogenous Surfactants | 126 | ||
| Specific Exogenous Surfactant Preparations | 127 | ||
| Hazards and Complications of Surfactant Therapy | 129 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 130 | ||
| Chapter 11: Corticosteroids in Respiratory Care | 137 | ||
| Chapter Objectives | 137 | ||
| Key Terms and Definitions | 137 | ||
| Clinical Indication for Use of Inhaled Corticosteroids | 138 | ||
| Physiology of Corticosteroids | 139 | ||
| Nature of the Inflammatory Response | 140 | ||
| Inflammation in the Airway | 140 | ||
| Aerosolized Corticosteroids | 140 | ||
| Pharmacology of Corticosteroids | 141 | ||
| Hazards and Side Effects of Steroids | 142 | ||
| Clinical Application | 142 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 143 | ||
| Chapter 12: Nonsteroidal Antiasthma Agents | 151 | ||
| Chapter Objectives | 151 | ||
| Key Terms and Definitions | 151 | ||
| Clinical Indication for Nonsteroidal Antiasthma Agents | 151 | ||
| Mechanisms of Inflammation in Asthma | 152 | ||
| Cromolyn-Like (Mast Cell–Stabilizing) Agents | 152 | ||
| Antileukotriene Agents | 153 | ||
| Monoclonal Antibodies | 155 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 155 | ||
| Chapter 13: Aerosolized Antiinfective Agents | 161 | ||
| Chapter Objectives | 161 | ||
| Key Terms and Definitions | 161 | ||
| Clinical Indications for Aerosolized Antiinfective Agents | 162 | ||
| Ribavirin | 163 | ||
| Palivizumab (Synagis) | 164 | ||
| Aerosolized Tobramycin | 164 | ||
| Aerosolized Aztreonam | 165 | ||
| Inhaled Zanamivir | 165 | ||
| Respiratory Care Assessment of Aerosolized Antiinfective Agents | 165 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 166 | ||
| Chapter 14: Antimicrobial Agents | 171 | ||
| Chapter Objectives | 172 | ||
| Key Terms and Definitions | 172 | ||
| Principles of Antimicrobial Therapy | 172 | ||
| Monitoring Response to Therapy | 174 | ||
| Antibiotics | 174 | ||
| Antimycobacterials | 177 | ||
| Antifungals | 177 | ||
| Antiviral Agents | 178 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 179 | ||
| Chapter 15: Cold and Cough Agents | 185 | ||
| Chapter Objectives | 185 | ||
| Key Terms and Definitions | 185 | ||
| Sympathomimetic (Adrenergic) Decongestants | 186 | ||
| Antihistamine Agents | 187 | ||
| Expectorants | 187 | ||
| Cough Suppressants (Antitussives) | 188 | ||
| Cold Compounds: Treating a Cold | 188 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 189 | ||
| Chapter 16: Selected Agents of Pulmonary Value | 193 | ||
| Chapter Objectives | 193 | ||
| Key Terms and Definitions | 193 | ||
| alpha1-Proteinase Inhibitor (Human) | 193 | ||
| Smoking Cessation Drug Therapy | 195 | ||
| Nitric Oxide | 196 | ||
| Iloprost (Ventavis) | 197 | ||
| Treprostinil (Tyvaso) | 197 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 198 | ||
| Chapter 17: Neonatal and Pediatric AerosolizedDrug Therapy | 203 | ||
| Chapter Objectives | 203 | ||
| Key Terms and Definitions | 203 | ||
| Introduction | 204 | ||
| Unlabled Use of Drugs in Neonatal and Pediatric Patients | 204 | ||
| Factors Affecting Neonatal and Pediatric Aerosol Drug Delivery | 205 | ||
| Clinical Response to Aerosolized Drugs in Neonatal and Pediatric Patients | 206 | ||
| Selection of Delivery Devices | 206 | ||
| Compliance and Cooperation During Aerosol Therapy | 207 | ||
| Aerosol Administration in Intubated Neonatal and Pediatric Patients | 208 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 208 | ||
| Unit 3: Critical Care, Cardiovascular,and Polysomnography Agents | 215 | ||
| Chapter 18: Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) | 215 | ||
| Chapter Objectives | 215 | ||
| Key Terms and Definitions | 215 | ||
| Uses of Neuromuscular Blocking Agents | 216 | ||
| Physiology of the Neuromuscular Junction | 217 | ||
| Nondepolarizing Agents | 217 | ||
| Depolarizing Agents | 218 | ||
| Neuromuscular Blocking Agents and Mechanical Ventilation | 218 | ||
| Monitoring of Neuromuscular Blockade | 219 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 220 | ||
| Chapter 19: Diuretic Agents | 227 | ||
| Chapter Objectives | 227 | ||
| Key Terms and Definitions | 227 | ||
| Renal Structure and Function | 228 | ||
| Diuretic Groups | 229 | ||
| Adverse Effects | 230 | ||
| Diuretics and Acute Respiratory Distress Syndrome | 231 | ||
| Diuretics and Chronic Lung Disease in Preterm Infants | 231 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 231 | ||
| Chapter 20: Drugs Affecting the Central Nervous System | 237 | ||
| Chapter Objectives | 237 | ||
| Key Terms and Definitions | 237 | ||
| Brain Structure and Function | 238 | ||
| Neurotransmitters | 239 | ||
| Psychiatric Medications | 239 | ||
| Ethyl Alcohol | 240 | ||
| Pain Treatment | 240 | ||
| Chronic Pain Syndromes | 242 | ||
| Anesthesia | 242 | ||
| Central Nervous System and Respiratory Stimulants | 243 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 243 | ||
| Chapter 21: Vasopressors, Inotropes, and Antiarrhythmic Agents | 249 | ||
| Chapter Objectives | 249 | ||
| Key Terms and Definitions | 249 | ||
| Overview of the Cardiovascular System and Factors Affecting Blood Pressure | 250 | ||
| Agents Used in the Management of Shock | 252 | ||
| Electrophysiology of the Myocardium | 252 | ||
| Pharmacology of Antiarrhythmics | 253 | ||
| Management and Pharmacotherapy of Advanced Cardiac Life Support | 254 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 254 | ||
| Chapter 22: Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics | 261 | ||
| Chapter Objectives | 261 | ||
| Key Terms and Definitions | 262 | ||
| Hypertension | 263 | ||
| Hypertension Pharmacotherapy | 263 | ||
| Epidemiology, Etiology, and Pathophysiology of Angina | 266 | ||
| Pharmacotherapy for Angina | 266 | ||
| Antithrombotic Agents | 267 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 269 | ||
| Chapter 23: Sleep and Sleep Pharmacology | 275 | ||
| Chapter Objectives | 275 | ||
| Key Terms and Definitions | 275 | ||
| History of the Treatment of Sleep Disorders | 276 | ||
| Neurophysiologic Mechanisms | 277 | ||
| Sleep Disorders: Causes and Treatments | 277 | ||
| National Board of Respiratory Care (NBRC) Testing Questions | 279 |